A: Time to first occurrence of albuminuria progression (change from normo- to micro- or macroalbuminuria or from micro- to macroalbuminuria) for linagliptin vs. placebo by eGFR subgroups. *P for interaction. B: Overall effects on eGFR (MDRD) slope from baseline to last value on treatment and by eGFR category G ≤ 2 to ≥ G4 for linagliptin (Lina) vs. placebo (pbo). C: Overall change from baseline in eGFR (MDRD) over time for linagliptin vs. placebo and comparison of acute vs. chronic slope differences. MMRM, mixed model for repeated measures; OC, observed case. *Adjusted mean eGFR slope based on MMRM including terms for time as a linear covariate, treatment, region, and baseline eGFR as categorical covariates, and treatment-by-time interaction, baseline eGFR-by-treatment interaction, baseline eGFR-by-time interaction, and baseline eGFR-by-treatment-by-time interaction.